Physician Views: With Dupixent nearing FDA approval, how is the US market for biologic asthma therapies evolving?

Formerly comprising only Roche's Xolair (first approved by the FDA in 2003), the US market for biologic therapies indicated for the treatment of moderate-to-severe asthma has undergone considerable change in recent years; thanks to the approval of GlaxoSmithKline's Nucala, Teva's Cinqair and AstraZeneca's Fasenra.

Further evolution is expected with Sanofi and Regeneron Pharmaceuticals' dupilumab (already marketed as Dupixent for the treatment of atopic dermatitis) awaiting approval by the FDA, with a decision expected next month at the latest.

Ahead of this key market catalyst, and six months after our last physician snap-poll in this field, we are taking the pulse of US-based pulmonologists to see how the market for biologic therapies is evolving and whether one of the recent launches is standing out ahead of its rivals. Competition among the new class of anti-IL-5 antibodies, particularly between Nucala and Fasenra, is intensifying.

Approximately what percentage of the moderate-to-severe asthma patients you currently manage is treated with a biologic therapy?


Using a five-point scale (1 = none / 5 = very significant increase), what impact has the availability of anti-IL-5 antibody products - Nucala (mepolizumab), Cinqair (reslizumab) and Fasenra (benralizumab) - had on your overall use of biologic therapies of the management of moderate-to-severe asthma?


Based on your experience with the anti-IL-5 class and their respective clinical/dosing profiles, do you consider one of the products to be superior to the others?

No - too early to tell

No - I’m confident they are comparable

Yes - Nucala (mepolizumab)

Yes - Cinqair (reslizumab)

Yes - Fasenra (benralizumab)

What percentage of moderate-to-severe asthma patients do you expect to treat with a biologic therapy in three years' time?


Using a five-point scale (1=none - 5= very significant), please rate your awareness of dupilumab as a potential future treatment option for moderate-to-severe asthma

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.